BioCentury
ARTICLE | Clinical News

AZX100: Interim Phase IIa data

December 20, 2010 8:00 AM UTC

Interim 7-month data from the ongoing, double-blind Phase IIa OL-ASCAR-03 trial in 150 patients showed that 3 mg AZX100 significantly improved scar total volume from baseline to 3 months and scar leng...